RLAY
Relay Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 7 to Apr 9 ▼ 2 days of insider sells: $257.5K by 1 insider, avg $13.19
- Apr 27 ▲ Relay Therapeutics announced positive clinical data from the zovegal…
- May 21 Activist stake: Relay Therapeutics Announces Pricing of Public Offering of…
- Jun 30 ▲ 4 funds open new positions (13F)
- Jun 30 to Jul 7 ▼ 3 days of insider sells: $2.4M by 4 insiders, avg $19.20
- Jul 16 Canaccord Genuity initiates
- Jul 28 ▼ 3 insiders sell $82.7K at $18.61
- Aug 14 to Aug 17 ▼ 2 days of insider sells: $1.3M by 2 insiders, avg $20.17
- Aug 25 to Aug 26 ▼ 2 days of insider sells: $116.5M by 2 insiders, avg $19.40
- Sep 8 ▼ 3 insiders sell $1.4M at $18.94
- Oct 6 to Oct 7 ▼ 2 days of insider sells: $1.2M by 2 insiders, avg $18.23
- Oct 28 ▼ 3 insiders sell $83.3K at $18.62
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $128.5M.
- InstitutionsBULLISH
Q2 2026: 48 added (4 new), 15 trimmed or exited. Largest new: Westfield Capital Management $62.6M, Polar Capital Holdings $33.5M.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.380 → −$0.354 over 90 days. 5 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −0.9% to 43.63M shares. 20.7 days to cover, ≈19.8% of shares.
- TrendRANGE
6% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 1.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $376.3M |
| STATE STREET CORP | ADD | $189.5M |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $144.2M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $88.4M |
| MORGAN STANLEY | DOUBLED | $72.1M |
| GOLDMAN SACHS GROUP INC | ADD | $63.8M |
| WESTFIELD CAPITAL MANAGEMENT CO LP | NEW | $62.6M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $54.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +68%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Jones Trading MAINTAIN | Buy |
| Aug 20, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 14, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 10, 2026 | Citizens MAINTAIN | Market Outperform |
| Aug 7, 2026 | Barclays MAINTAIN | Overweight |
| Jul 21, 2026 | Goldman Sachs MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Bergstrom Donald A President, R&D Oct 28, 2026 | SELL | $41.9K |
Catinazzo Thomas Chief Financial Officer Oct 28, 2026 | SELL | $27.4K |
Rahmer Peter See remarks Oct 28, 2026 | SELL | $14.0K |
Patel Sanjiv President and CEO Oct 7, 2026 | SELL | $872.4K |
Catinazzo Thomas Chief Financial Officer Oct 6, 2026 | SELL | $325.4K |
Catinazzo Thomas Chief Financial Officer Oct 6, 2026 | SELL | $4.0K |
Bergstrom Donald A President, R&D Sep 8, 2026 | SELL | $161.8K |
Patel Sanjiv President and CEO Sep 8, 2026 | SELL | $912.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.35 | -$0.40–-$0.26 | +6.7% | $5.9M |
| Next Q | -$0.38 | -$0.41–-$0.35 | +2.5% | $720.0K |
| Current FY | -$1.56 | -$1.64–-$1.44 | +3.6% | $6.9M |
| Next FY | -$1.57 | -$1.80–-$1.15 | +3.7% | $10.6M |
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 5 press releases · 2 bullish · 4 bearish · 9 neutral- NEUTRAL SC 13GNov 16, 2026
T. Rowe Price Investment Management disclosed a passive 8.2% stake in Relay Therapeutics as of September 30, 2026, representing 17,868,157 shares. This is a new 13G filing (not an amendment), indicating the fund crossed the 5% threshold.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 4, 2026
Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the…
Watch for the ASH 2026 presentation on Dec 14 for updated zovegalisib data in vascular anomalies and the accompanying regulatory update, which could clarify the path to approval. Monitor enrollment…
- NEUTRAL PRESS-RELEASENov 4, 2026
Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the $0.43…
Monitor the ASH presentation on Dec 14 for updated vascular anomalies data and the regulatory update that follows; also watch for the Phase 3 1L breast cancer trial design confirmation by year-end…
- NEUTRAL INST-CLUSTERNov 3, 2026
Three asset managers increased their RLAY positions in Q3 2026, adding a net $1.9M in holdings…
The cluster is small and stale (Q3 2026 data disclosed with 45-day lag). Monitor next 13F filing for continuation or reversal of this modest accumulation trend.
All RLAY filing & press-release reports (20)
- SC 13G reportNov 16, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- INST-CLUSTER reportNov 3, 2026
- 144 reportOct 7, 2026
- 144 reportOct 6, 2026
- CLUSTER reportSep 9, 2026
- CLUSTER reportAug 28, 2026
- CLUSTER reportAug 18, 2026
- CLUSTER reportJul 8, 2026
- 144 reportJun 22, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportMay 21, 2026
- PRESS-RELEASE reportMay 20, 2026
- 424B5 reportMay 19, 2026
- PRESS-RELEASE reportMay 19, 2026
- PRESS-RELEASE reportMay 19, 2026
- 8-K reportApr 27, 2026
- PRESS-RELEASE reportApr 27, 2026
- PRESS-RELEASE reportMar 16, 2026